Nikolaeva TG **, Vichinckaya GV*, Strunina IV

METABRE and BRECOSM are two EU fun -
ded consortia aimed at investigating the mole -
cular mechanisms of organ-specific breast
cancer metastases and identify new diagno -
stic and therapeutic determinants to prevent
and/or cure this detrimental disease. The con -
ference programme will focus on new molecu -
lar and translational aspects and is expected
to attract both basic and clinical scientists.
MetaBre/BRECOSM
Breast Cancer and
Metastasis Conference
Rome, 5-7 December 2007
CNR - Consiglio Nazionale delle Ricerche
Piazzale Aldo Moro n.7 - Rome (Italy)

_________________________________________________________________________________________
SUPPORTED BY
AICR - Association for International Cancer Research
AMGEN
ASTRAZENECA S.P.A
BACR - The British Association for Cancer Research
BERTOLD TECHNOLOGIES
BRECOSM
CEPHALON
CHARLES RIVER
CINBO - Consorzio Interuniversitario Nazionale per la Bioncologia
EACR - European Association for Cancer Research
METABRE
M-MEDICAL
MRS - Metastasis Research Society
SANOFI-aventis
SIAL
TEMA RICERCA
TOPOTARGET
XENOGEN
1

MetaBre/BRECOSM
Breast Cancer and
Metastasis Conference Rome, 5-7 December 2007
5 December 2007
_________________________________________________________________________________________
CINBO - Consorzio Interuniversitario Nazionale per la Bioncologia - Satellite Symposium
Educational Course: Clinical Management of Breast Cancer Bone Metastasis: today and tomorrow
Sponsored by Astrazeneca S.p.a.
Chair: Stefano Iacobelli (Chieti, Italy), Anna Teti (L’Aquila, Italy)
8.50 Introduction
9.00 Toshyuki Yoneda Biological insights into breast cancer bone metastasis
(Osaka, Japan)
9.30 Corrado Ficorella Issues addressing the use of chemotherapy and hormone
(L’Aquila, Italy) therapy
9.50 Riccardo Maurizi Enrici Issues addressing the use of radiotherapy
(Rome, Italy)
10.10 Coffee break
10.30 Giampaolo Tortora Anti-erbB and antiangiogenetic drugs
(Napoli, Italy)
10.50 Paolo Marchetti Bisphosphonates and innovative drugs
(Rome, Italy)
11.10 General discussion and closing remarks
_________________________________________________________________________________________
12.20 Welcome to the MetaBre/BRECOSM Conference and Introductory Remarks
Anna Teti (L’Aquila, Italy), Jonathan Sleeman (Karlsruhe, Germany)
_________________________________________________________________________________________
Experimental models
Chair: Gabri van der Pluijm (Leiden, The Netherlands), Peter ten Dijke (Leiden, The Netherlands)
12.30 Jos Jonkers Mouse models of breast cancer
(Amsterdam, The Netherlands)
13.00 Peter Friedl Imaging of migrating tumor cells
(Wurzburg, Germany)
13.30 Ruggero De Maria Identification and expansion of cancer-initiating cells
(Rome, Italy)
2

Oral Communications
Chair: Philippe Clement-Lacroix (Romainville, France), John Collard (Amsterdam, The Netherlands)
14.00 Anna Fantozzi Generation of transgenic mouse models to dissect organ
(Basel, Switzerland) specific metastasis and EMT in mammary gland tumors
14.10 Agnes Noël Vascular architecture of breast cancer xenografts over-
(Liège, Belgium) expressing MT4-MMP
14.20 Françoise Bruyère The lymphatic ring assay: a 3D culture system for discovering
(Liège, Belgium) novel genetic mechanism that regulate lymphangiogenesis
14.30 Lenaic Paon Towards identifying a possible new mechanism for lymph node
(Bemont, UK) metastasis in human breast tumour xenograft models
_________________________________________________________________________________________
14.45-15.15 Break
_________________________________________________________________________________________
Mechanisms inducing breast cancer
Chair: Enrico Ricevuto (L’Aquila, Italy), Eugene Lukanidin (Copenhagen, Denmark)
15.15 Matthew Smalley Breast tumor stem cells
(London, UK)
15.45 Carlo M. Croce MicroRNA expression and function in cancer
(Columbus, USA)
16.15 David Lyden The pre-metastatic niche
(New York, USA)
Oral Communications
Chair: Marc Bracke (Gent, Belgium), Charles DeCraene (Paris, France)
16.45 Amy S. Yee
(Boston, USA)
The HBP1 transcriptional repressor and invasive breast cancer
16.55 Mejdi Moumen Perturbation of β-catenin and p53 pathways in basal mammary
(Paris, France) cells: effects on mammary development and tumorigenesis
17.05 Vincent Castronovo HDAC7 silencing alters endothelial cell migration, a key step of
(Liège, Belgium) angiogenesis
17.15 Anna C. Matos Salim Global DNA methylation analysis in breast tumors using
(São Paulo/Brazil) promoter microarray
_____________________________________________________________________________________
17.30-18.30 Posters
3

6 December 2007
_________________________________________________________________________________________
New prognostic tools
Chair: Rosette Lidereau (St. Cloud, France), Geert Berx (Gent, Belgium)
8.30 René Bernards Breast cancer prognosis by microarray analysis
(Amsterdam, The Netherlands)
9.00 Joaquìn Dopazo Functional interpretation of microarray experiments
(Valencia, Spain)
9.30 Kent W. Hunter Inherited predisposition for breast cancer progression
(Bethesda, USA)
Oral Communications
Chair: Maciej Ugorski (Wroclaw, Poland), Roland Stauber (Frankfurt am Main, Germany)
10.00 Mattia Capulli Gene signature of bone metastasis discloses predisposition of
(L’Aquila, Italy) basal-like subtype of breast carcinoma in generating metastases
in different organs
10.10 Pavel Gromov Omics-based profiling of carcinoma of the breast and regional
(Copenhagen, Denmark) lymph node metastasis
10.20 Soraya Sin c20orf42/kind1 is a marker of breast cancer lung metastasis
(St. Cloud, France) identified by gene profiling and functionally validated
_________________________________________________________________________________________
10.30-11.00 Break
_________________________________________________________________________________________
Metastatic disease
Chair: Angels Sierra (Barcelona, Spain), Massimo Zollo (Napoli, Italy)
11.00 Patricia S. Steeg Mechanistic insights and clinical challenges of tumor
(Bethesda, USA) metastases
11.30 Max S. Wicha Breast cancer stem cells- implications for prevention and
(Ann Arbor, USA) therapy
12.00 Toshyukii Yoneda Breast cancer bone metastases
(Osaka, Japan)
Oral Communications
Chair: Pavel Gromov (Copenhagen, Denmark), Frans van Roy (Gent, Belgium)
12.30 Richard Bachelier Role of VEGF and its receptors in breast cancer bone
(Lyon, France) metastasis formation
12.40 Adriano Angelucci Regulation of CD147/EMMPRIN and its downstream genes by
(L’Aquila, Italy) RANKL in human osteotropic tumour cells
12.50 Marco Falasca Role of phospholipase Cγ1 in cell metastasis
(London, UK)
4

13.00 Geert Berx Functional analysis of EMT-inducing transcription factors in
(Ghent, Belgium) invasion and metastasis of breast cancer
_________________________________________________________________________________________
13.15-14.30 Lunch and Posters
_________________________________________________________________________________________
Lymphangiogenesis
Chair: Sue Eccles (Belmont, UK), Gerhard Christofori (Basel, Switzerland)
14.30 Michael Detmar
(Zurich, Switzerland)
Pathways targeting tumor lymphangiogenesis
15.00 Douglas M. Noonan Mechanisms of angiogenesis for cancer therapy and prevention
(Varese, Italy)
15.30 Elisabetta Dejana
(Milan, Italy)
Endothelial cadherins and tumor angiogenesis
_________________________________________________________________________________________
16.00-16.30 Break
_________________________________________________________________________________________
Dissemination of FP6 results
Chair: Anna Teti (MetaBre Coordinator), Jonathan Sleeman (BRECOSM Coordinator)
16.30-16.50 Jonathan Sleeman BRECOSM: identifying the roots of organ-specific metastasis of
(Karlsruhe, Germany) breast cancer
16.50-17.10 Gerhard Christofori Molecular dissection of breast cancer invasion
(Basel, Switzerland)
17.10-17.30 Peter ten Dijke TGF-β signaling in breast cancer
(Leiden, The Netherlands)
17.30-17.40 Anna Teti MetaBre: Molecular mechanisms involved in organ-specific
(L’Aquila, Italy) metastatic growth processes in breast cancer
17.40-18.00 Keltouma Driouch Organ-specific metastatic gene and protein signatures in breast
(St. Cloud, France) cancer
18.00-18.20 Akeila Bellahcène Functional analysis of organ-specific metastatic genes
(Liège, Belgium)
18.20-18.30 General discussion and closing remarks
5

7 December 2007
________________________________________________________________________________________
Genetic and epigenetic regulators
Chair: Vincent Castronovo (Liège, Belgium), Agnes Noel (Liège, Belgium)
8.30 Howard Y. Chang Genetic regulators of large-scale transcriptional signatures in
(Stanford, USA) cancer
9.00 Alexandra Pietersen Epigenetic gene silencers and cancer
(Amsterdam, The Netherlands)
9.30 Jiri Bartek Genotoxic stress and cancer
(Copenhagen, Denmark)
10.00 Bruce Ponder Genetic susceptibility to breast cancer
(Cambridge, UK)
10.30 Danny Welch
(Birmingham, USA)
Metastasis suppressor genes
_________________________________________________________________________________________
11.00-11.30 Break
_________________________________________________________________________________________
Targeted therapy
Chair: Philippe Clezardin (Lyon, France), Bernd Hentsch (Frankfurt am Main, Germany)
11.30 Peter Carmeliet Principles and therapeutic implications of angiogenesis in
(Leuven, Belgium) cancer
12.00 Peter Sicinski Targeting cyclins in breast cancer
(Boston, USA)
12.30 Paolo Comoglio The Met pathway: master switch and drug target in cancer
(Torino, Italy) progression
_________________________________________________________________________________________
13.00-14.00 Lunch
_________________________________________________________________________________________
Oral Communications
Chair: Anna Teti (L’Aquila, Italy), Jonathan Sleeman (Karlsruhe, Germany)
14.00 Alicia González-Martín CCL5 overexpression reduces tumor growth by regulating
(Madrid, Spain) CCR5-mediated selective infiltration of immune system cells
14.10 Gabri van der Pluijm BMP7, a putative regulator of epithelial homeostasis in the
(Leiden, The Netherlands) human breast, is a potent inhibitor of breast cancer bone
metastasis in vivo
14.20 Alfiya Safina Regulation of tumor microenvironment by TGF-β1 signaling in
(Buffalo, USA) tumour cells
14.30 Chantal Achermann Assessing the role of Tissue Inhibitor of Metalloprotease-1
(Basel, Switzerland) (Timp-1) during epithelial-mesenchymal transition
14.40 Massimo Zollo Understanding h-prune biology to fight breast cancer metastasis
(Napoli, Italy)
6

14.50 Roland H. Stauber Reduced expression of BRMS1 in breast cancer metastases is
(Frankfurt am Main, Germany) caused by epigenetic silencing
15.00 Noona Ambartsumian Role of tumor stroma fibroblasts in metastasis formation
(Copenhagen, Denmark)
15.10 Philippe Clézardin A cathepsin K inhibitor reduces breast cancer-induced
(Lyon, France) osteolysis and skeletal tumour Burden
15.20 Philippe Pujuguet A nonpeptide RGD integrin antagonist inhibits bone metastasis
(Romainville, France) formation through osteoclasts dependent and independent
mechanisms and achieves maximum efficacy when combined
with zoledronate
15.30 Antonio Saha Development and characterization of peptides for targeting αvβ6
(London, UK) in cancer
_________________________________________________________________________________________
15:40 Close
POSTERS
P001 FUNCTIONAL CHARACTERIZATION OF THE GPI-ANCHORED MATRIX
METALLOPROTEINASES MT4-MMP AND MT6-MMP
A. De Lisio 1 , M. Mazzone 1 , G. Giacchetti 1 , C.Zurzolo 2 , R. Buccione 1 .
1 Consorzio Mario Negri Sud, Tumor Cell Invasion Laboratory, Department of Cell Biol. and Oncol.
S. Maria Imbaro (Ch), Italy ; 2 Unité de Trafic Membranaire et Pathogénése, Institut Pasteur, 75724
Paris Cedex 15, France
P002 INVADOPODIA AS SPECIALIZED MEMBRANE DOMAINS
Giusi Caldieri , Giada Giacchetti, Massimiliano Baldassarre and Roberto Buccione
Tumor Cell Invasion Laboratory, Department of Cell Biology and Oncology, Consorzio Mario Negri
Sud, S. Maria Imbaro, via Nazionale 8/A, 66030 Chieti, Italy
P003 COMPARATIVE PROTEOMICS OF INVADOPODIA BY DIFFERENCE GEL
ELECTROPHORESIS (DIGE)
Francesca Attanasio and Roberto Buccione
Tumor Cell Invasion Laboratory Dept. of Cell Biology and Oncology Consorzio Mario Negri Sud
(CMNS), Via Nazionale 8/A, 66030 Chieti, Italy
P004 BREAST CANCER METASTASIS SUPPRESSOR 1 (BRMS1) MODULATES SIGNALING
PATHWAYS IMPORTANT FOR METASTASIS
Kedar S. Vaidya 1, Douglas R. Hurst 1, Yi Xie, Alexandra Silveira, Blake P. Moore, Alka Mehta, and
Danny R. Welch
Departments of Pathology, Cell Biology and Pharmacology and Toxicology; Comprehensive Cancer
Center and National Foundation for Cancer Research, Center for Metastasis Research University of
Alabama at Birmingham
P005 ANTITUMOR EFFECTS OF BONE-TARGETED NANOPARTICLES LOADED WITH
DOXORUBICIN ON BREAST CANCER CELL LINES
M. Salerno1, C. Fotia1, E. Cenni1, D. Granchi1, S. Avnet1, F. Castelli3, D. Micieli3, M.D.
Sarpietro3, R. Pignatello3, N. Baldini1,2
1Pathophysiology Lab, Istituti Ortopedici Rizzoli, Bologna, Italy; 2Dept. of Orthopaedic Surgery,
Istituti Ortopedici Rizzoli and University of Bologna, Bologna, Italy; 3Dept. o f Pharmaceutical
Sciences, University of Catania, Catania, Italy
P006 SIGNAL TRANSDUCTION IN BREAST CANCER CELLS – INFLUENCE OF
RECOMBINANT HUMAN ERYTHROPOIETIN
Španinger Klemen1, Berne Sabina2, Komel Radovan2, Debeljak Nataša1
7

1 Center for functional genomics and bio-chips, Faculty of medicine, University of Ljubljana,
Ljubljana, Slovenia; 2 Medical centre for molecular biology, Faculty of medicine, University of
Ljubljana, Ljubljana, Slovenia
P007 ErbB2 LIGANDS AS NEW POTENTIAL TARGETS FOR THE METASTASIS-
PROMOTING S100A4 PROTEIN
Jörg Klingelhöfer1, Henrik D. Møller1, Eren U. Sumer2, Noona Ambartsumian1 and Eugene M.
Lukanidin1.
1 Department for Molecular Cancer Biology, Danish Cancer Society, Copenhagen, Denmark; 2
Nordic Bioscience Diagnostics, Herlev, Denmark.
P008 ALTERNATIVE EXPRESSION OF DLX2 AND DLX5 IN MDA-MB-231 MAMMARY
TUMOR CELLS AND METASTASIS
Morini, M.1,2, Barbieri O.1,2, Delucchi F.2, Emionite L.2, Levi G.3, Astigiano S.2
1Dipartimento di Medicina Sperimentale, Università di Genova, 2Istituto Nazionale per la Ricerca
sul Cancro, Genova and 3Regulations de la Morphogenese, UMR5166 CNRS/MNHN, Paris,
France.
P009 IMPLICATION OF S100A4 IN CROSSROADS OF CANCER AND CHRONIC
INFLAMMATION: SIGNIFICANCE FOR METASTATIC PROGRESSION
Klingelhöfer J., 1, Šenolt L.,2,4, Baslund B.,3 Skibshøj I., 1 Gay S., 4 Ambartsumian N., 1 Schmidt
Hansen B.,1 Lukanidin E.,1 Mariam Grigorian
1Danish Cancer Society, Strandboulevarden 49, Copenhagen 2100, Denmark; 2Institute of
Rheumatology, Na Slupi 4 128 50 Prague, Czech Republic; 3Dept of Rheumatology,
Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark; 4Center of Experimental Rheumatology,
Zürich Center for Integrative Human Physiology (ZIHP) University Hospital, Zürich, Switzerland.
P010 SOLUBLE CADHERINS AS CANCER BIOMARKERS
De Wever Olivier1*, Derycke Lara1*, Hendrix An2, De Meerleer Gert3, Godeau François5,
Depypere Herman4, Bracke Marc1
Laboratory of Experimental Cancer Research1, Department of Medical Oncology2, Department of
Radiotherapy and Nuclear Medicine3, and Department of Gynaecology4, University Hospital Ghent,
De Pintelaan 185, 9000 Gent, Belgium. INSERM U515, Hôpital Saint-Antoine5, Rue du Faubourg
184, 75571 Paris, France
P011 TRANSCRIPTIONAL ANALYSIS OF BASAL-TYPE MAMMARY HYPERPLASIA
INDUCED BY CONSTITUTIVE ACTIVATION OF WNT/BETA-CATENIN SIGNALING
Marisa M. Faraldo, Cécile Laurent, Charles Decraene, Amandine di Cicco, Valérie Petit, Marie-
Ange Deugnier, Marina A. Glukhova
Institut Curie, Paris, France
P012 DOWN-REGULATION OF HIF-1α EXPRESSION, THROUGH mTOR PATHWAY, BY
LETROZOLE (Femara®) IN ER+ve BREAST CANCER (BC) PATIENTS
Daniele Generali, Roberto Giardin, Alfredo Berruti, Stephen B. Fox, MariaPia Brizzi, Manuela
Milani, Simone Bonardi, Alessandra Bersiga, Rossana Dionisio, Sergio Aguggini, Giovanni Allevi,
Luigi Dogliotti, Alberto Bottini and Adrian L. Harris
Unità di Patologia Mammaria, Senology and Breast Cancer Unità, Breast Research Laboratory,
Istituti Ospitalieri di Cremona, Viale Concordia 1,26100 Cremona (Italy)
P013 A ROLE OF ENDOSIALIN (CD248) IN THE INTERACTION BETWEEN PERICYTES AND
ENDOTHELIAL CELLS IN THE ANGIOGENIC VASCULATURE
Nicole Simonavicius, Ivo Huijbers and Clare M. Isacke
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road,
London SW3 6JB
P014 ROLE OF Smad4 IN HUMAN BREAST CANCER METASTASIS
Johannes Fritzmann, Frauke Kosel 2 , Walter Birchmeier 2 , Peter M. Schlag 1
1: Charité Medical School Berlin, Dept. for Surgery and Surgical Oncology; 2: Max Delbrück Center
for Molecular Medicine, Berlin-Buch
8

P015 ROLE OF CLEVER-1 IN TUMOUR ADHESION TO LYMPHATIC AND BLOOD
ENDOTHELIA
A Ammar 1 , R Mohammad 1 , M Salmi 2 , M Pepper 3 , R Nissato 4 , GB Nash 5 , E Parish 1 , P Patel 1 , SG
Martin 1‡
1 Univ. of Nottingham; 2 Turku University, Finland; 3 NetCare Molecular Med Inst, South Africa;
4 Integrative Biosciences Inst, Switzerland, 5 Univ of Birmingham.
P016 CHARACTERIZATION OF NOVEL GENES DIFFERENTIALLY EXPRESSED IN BREAST
CELL LINES EXPRESSING DIFFERENT LEVELS OF c-erbB2
A.P.M.Silva 1 , L.C. Pires 1 , C.V.Jongeneel 3 , S.J.de Souza 2 , AA Camargo 1 , P. S Jat and M. O´Hare.
1 Laboratory of Molecular Biology and Genomics, Ludwig Institute for Cancer Research, Sao Paulo;
2 Laboratory of Computational Biology, Ludwig Institute for Cancer Research, Sao Paulo; 3
Bioinformatic Institute, Ludwig Institute for Cancer Research, Switzerland.
P017 ROLE OF LYMPHATIC VESSELS IN BREAST CANCER PROGRESSION
Rabab A.A.Mohammed*+; Somaia Elsheikh+; Muhammad S Gill+, Andrew R Green+, Emma C
Paish+, Ian O Ellis+ and Stewart G Martin*
*Clinical Oncology and +Histopathology Departments, University of Nottingham, University
Hospitals, City Hospital Campus, Hucknall Road, NG5 1PB, Nottingham, UK
P018 PREVALENCE OF BRCA1/BRCA2 PREDISPOSING MUTATIONS ACCORDING TO
FAMILY HISTORY AND CLINICAL CRITERIA OF BREAST/OVARIAN CANCER RISK
Sidoni T, De Marchis L 2 , Midulla C 2 , Capalbo C 1 , Paris I 5 , Ronzino G 4 , Di Seri M 2 , Tomao S 2 ,
Meggiorini M.L, Scambia G 3 , Ficorella C, Marchetti P 5 , Cortesi E 2 , Frati L 2 , Gulino A 1 , Giannini G 1
and Ricevuto E.
Medical Oncology, University L’Aquila; 1 Service Molecular and Ultrastructural Pathology, Dept.
Experimental Medicine and Pathology, University “La Sapienza”, Rome, Italy; 2 Medical Oncology,
University “La Sapienza”, Rome, Italy; 3 Oncology, UCSC, Campobasso, Italy; 4 Oncology, S. Carlo
Hospital, Rome, Italy; 5 Oncology, S.Andrea Hospital, Rome, Italy
P019 IDENTIFICATION OF CELL MEMBRANE PROTEINS DIFFERENTIALLY EXPRESSED IN
OSTEOTROPIC HUMAN BREAST CANCER CELLS USING A PROTEOMIC APPROACH
Philippe Kischel 1 , Aude Sauvage 1 , Rowan Dobson 2 , Akeila Bellahcène 1 , Philippe Clézardin 3 , Edwin
De Pauw 2 , & Vincent Castronovo 1
1 Metastasis Research Laboratory, Center for Experimental Cancer Research, University of Liege,
Bat. B23, CHU Sart Tilman Liège, B-4000 Liège, Belgium; 2 Laboratory of Mass Spectrometry,
Department of Chemistry, University of Liege, Bat. B6c, B-4000 Liège, Belgium; 3 INSERM
Research Unit 403, Faculté de Médecine Laënnec, F-69372 Lyon Cedex 08, France.
P020 REGULATION OF CXCL8/IL-8 BY ZONULA OCCLUDENS-1 IN BREAST TUMOR
CELLS
Bindels S.1, Mestdagt M.1, Hunziker W.3, Noël A.1, Birembaut P.2, Foidart J.M.1 , Polette M.2 and
Gilles C1
1 Laboratory of Developmental and Tumor Biology, CRCE, University of Liège, Sart Tilman, B-4000
Liège, Belgium; 2 Unité I.N.S.E.R.M. U514, Laboratoire Pol Bouin, I.F.R. 53, C.H.U. Maison
Blanche, 51100 Reims, France; 3 Institute of Molecular and Cell Biology, Epithelial Cell Biology
Laboratory, Singapore, Singapore.
P021 BREAST TUMOR PROGRESSION ASSOCIATED WITH LOSS OF ADAM23
EXPRESSION: THE BIOLOGICAL ROLE FOR THIS PUTATIVE METASTASIS SUPPRESSOR
GENE
Érico Tosoni Costa1, Newton Verbisck1, AG Muras3, RP Moura1, FF Costa1, FHM de Melo2, SM
Zanata4, MC Sogayar3, R Chammas2 and AA Camargo1
1Laboratory of Molecular Biology and Genomics, Ludwig Institute for Cancer Research, Sao Paulo;
2Laboratory of Experimental Oncology, University of Sao Paulo Faculty of Medicine; 3Chemistry
Institute, University of São Paulo; 4Laboratory of Neurobiology, Federal University of Paraná, Brazil.
9

P022 THE ROLE OF SIALYL LEWISA ANTIGEN IN THE FORMATION OF BREAST CANCER
METASTASES
Lukasz Wojciech 1 , Anna Laskowska 2 , Nick V. Henriquez 3 , Gabri van der Pluijm 3 , Maciej Ugorski 1,2
1 Department of Biochemistry, Pharmacology and Toxicology, Faculty of Veterinary Medicine,
Wroclaw University of Enviromental and Life Sciences, Wroclaw, Poland; 2 Department of
Immunochemistry, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish
Academy of Science, Wroclaw, Poland; 3 Department of Endocrinology, Leiden University Medical
Centre, Leiden, Netherlands.
P023 A SINUSOIDAL 2mT ELECTROMAGNETIC FIELD INHIBITS IN VITRO ANGIOGENESIS
PROCESS
*Simona Delle Monache, *Roberto Iorio, °Riccardo Alessandro, § Fabrizio Mancini and *Rosella
Cardigno Colonna.
*Department of Biomedical Sciences and Technology, University of L'Aquila, L'Aquila, Italy
§ Department of Electric and Information Engineering, University of L'Aquila, L'Aquila, Italy
° Department of Biopathology and Biomedical Methodology, University of Palermo, Palermo, Italy
P024 ORGAN-SPECIFIC PROTEIN-PROTEIN INTERACTION NETWORKS: A FUNCTIONAL
APPROACH OF BREAST CANCER METASTASIS COUPLING PROTEOMIC AND GENOMIC
INFORMATION
Rebeca Sanz 1 , Ramón Aragüés 2 , Sergi Franco 3 , Xavier Massagué 3 , Thomas Landemaine 4-5 ,
Keltouma Driouch 4-5 , Baldo Oliva 2 and Àngels Sierra 1 .
1 IDIBELL, Hosp. Duran I Reynals, C.S.U.B., 08907 L’Hospitalet Ll., Barcelona, Spain; 2 Structural
bioinformatics Lab. (GRIB). Universitat Pompeu Fabra-IMIM. Barcelona Research Park of
Biomedicine (PRBB). Barcelona, Catalonia, SpaiN; 3 UPC (Universitat Politécnica de Catalunya),
LSI (Departament de Llenguatges i Sistemas Informatics), Barcelona, Spain ; 4 Centre René
Huguenin, FNLCC, Saint-Cloud, France ; 5 INSERM, U735, Saint-Cloud, France.
P025 CAUSE-EFFECT OF Prx2 IN BREAST CANCER CELLS METASTASIZING TO LUNGS
Baltziskueta E 1 , Rubio N 2 , Stresing V 1 , Blanco J 2 & Sierra A 1
1 2
Centro de Oncología molecular-IDIBEL, Cardiovascular Research Center (CSIC-ICCC),
Barcelona
P026 LOSS OF CD24 EXPRESSION PROMOTES DUCTAL BRANCHING IN THE MURINE
MAMMARY GLAND
Natascha Cremers a , Marie-Ange Deugnier b and Jonathan Sleeman a *.
a Forschungszentrum Karlsruhe, Institut für Toxikologie und Genetik, Postfach 3640, D-76021
Karlsruhe, Germany; b Institut Curie, UMR144 CNRS, 26 rue d'Ulm, 75248 Paris Cedex 05, France
P027 THE ROLE OF PIP92 IN TUMOR METASTASIS
Antje Neeb 1 , Natascha Novac 1 , Ingmar Scholl 1 , Johannes Fritzmann 2 , Peter Schlag 2 and Jonathan
Sleeman 1
1 Research Center Karlsruhe, Institute for Toxicology and Genetics, Karlsruhe, Germany; 2 Robert-
Rössle-Clinic, Humboldt-University, Charité, Berlin, Germany
P028 TRACKING OF TUMOR CELLS TO DETERMINE THE CONTRIBUTION OF TUMOR
CELLS TRAFFICKING THROUGH THE LYMPHATICS TO THE DEVELOPMENT OF
METASTASES IN VITAL ORGANS
Nicole Grau and Jonathan Sleeman
Research Center Karlsruhe, Institute for Toxicology and Genetics, Karlsruhe, Germany
P029 DIACYLGLYCEROL KINASE ALPHA IS REQUIRED FOR PROLIFERATION AND
INVASION INDUCED BY GROWTH FACTORS AND CHEMOKINES
Paolo E. Porporato, Federica Chianale, Gabriella Ranaldo, Cecilia De Antonio, Chiara Ambrogio*,
Nicoletta Filigheddu, Elena Rainero, Sara Traini, Gianluca Baldanzi, Andrea Graziani
Department of Medical Sciences, University Amedeo Avogadro of Piemonte Orientale, v. Solaroli
17, 28100, Novara, Italy; *Center for Experimental Research and Medical Studies, University of
Turin, Turin, Italy
10

P030 ROLE OF TUMOR TGF-β1 SIGNALING IN TUMOR MICROENVIRONMENT AND
METASTASIS
Alfiya Safina, Andrei V. Bakin
Roswell Park Cancer Institute, Buffalo, NY 14263
P031 FOCAL ADHESION KINASE MEDIATES ADHESION AND CELL SPREADING OF
BONEMETASTATIC BREAST CARCINOMA CELLS
Mora EM*,**, Sanguino A***, Rivera M **, Castro C**, Lopez-Berestein G***, Sood A.****
University of Puerto Rico Comprehensive Cancer Center*, Department of Surgery of the School of
Medicine of the University of Puerto Rico**, Department of Experimental Therapeutics ***, and the
Department of Gynecology****, UT MD Anderson Cancer Center, Houston, Texas
P032 EXPRESSION OF THE INTEGRIN ALPHAVBETA6 IN BREAST CANCER CELLS
PROMOTES INVASION, IS AN INDEPENDENT MARKER OF POOR SURVIVAL AND
PROVIDES A NEW TARGET FOR THERAPY
JF Marshall1, GJ Thomas1, SW Duffy1, P Chou1, R Gabe1, IO Ellis2, AR Green2, A Saha1, K
Mulligan1, K Ryder3, C Gillet3, S Violette4, P Weinreb4, LJ Jones1
1Institute of Cancer, Barts and London Medical and Dental School, London; 2Dept. Of
Histopathology, Nottingham; 3Hedley Atkins Breast Pathology, Guys’ Hospital, London; 4Biogen
Idec, Cambridge, Mass. USA
P033 CHARACTERIZATION OF A NEW GENE SIGNATURE FOR THE BASAL PHENOTYPE
Laurent C 1, Decraene C 1,2, Meyniel J-P 2, Zinovyev A 3, Barillot E 3 and Thiery J-P1 2
Institut Curie: CNRS-UMR 144 (1), Translational Research department (2), Bio-informatics (3)
P034 TUMOR-BONE INTERACTIONS IN THE FORMATION OF BONE METASTASIS
Niek V. Henriquez 2 , Christel van den Hoogen 1 , Geertje van der Horst 1 , Welmoed van Deen 2 , Jeroen
T. Buijs 1 , Gabri van der Pluijm 1,2 .
1.Dept. Urology, Leiden University Medical Center, Leiden, The Netherlands; 2.Dept.
Endocrinology, Leiden University Medical Center, Leiden, The Netherlands
P035 WHOLE-BODY OPTICAL IMAGING IN BREAST AND PROSTATE CANCER
PROGRESSION AND BONE METASTASIS
Jeroen T. Buijs 1 , Niek V. Henriquez 2 , Geertje van der Horst 1 , Christel van den Hoogen 1 , Petra G.M.
van Overveld 1 , Henry Cheung 1 , Ivo Que 2 , Eric L. Kaijzel 2 , Clemens W.G.M. Löwik 2 , Gabri van der
Pluijm 1,2
1 2
Departments of Urology J3-100, and Endocrinology and Metabolic Diseases, Leiden University
Medical Center, Leiden, the Netherlands
P036 DEXORUBICIN AND ZOLEDRONIC ACID EXERT DIFFERENTIAL EFFECTS ON
EXTRA-OSSEOUS VS INTRA-OSSEOUS BREAST TUMOUR GROWTH IN VIVO
Penelope Ottewell, Blandine Deux, Hannu Monkkonen Robert E Coleman, Philippe Clezardin,
Ingunn Holen.
Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of
Sheffield, Sheffield S10 2RX, UK
P037 SEQUENTIAL USE OF DEXORUBICIN AND ZOLEDRONIC ACID INHIBITS
SUBCUTANEUS TUMOUR GROWTH IN BREAST CANCER MODELS IN VIVO
Ingunn Holen, Diane V. Lefley, Robert E Coleman, Penelope D Ottewell
Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences, University of
Sheffield, Sheffield S10 2RX, UK
P038 BIOLOGIC PARAMETERS OF TUMOR CELLS IN ADVANCED BREAST CANCER
Nikolaeva T.G. **, Vichinckaya G.V.*, Strunina I.V. **
* N.N. Blokhin Memorial Cancer Research Center of Russian Federation,RAMS, Moscow , Russia;
** Advanced Biomedical Researches Laboratory, Cell Biology, Moscow, Russia
P039 ANNEXIN A1- A KEYPLAYER IN MAMMARY TUMORIGENESIS AND PROGRESSION
Maschler S., Gebeshuber C., Beug H.
11

Research Institute of Molecular Pathology (IMP), Vienna, Austria
P040 THE SCAFFOLDING PROTEIN NHERF1 FUNCTIONS AS A MASTER SWITCH TO
PROGRAM DIFFERENT PHENOTYPES IN METASTATIC BREAST CELLS VIA ITS PDZ
DOMAINS
Cardone RA 1 , Rucci N 2 , Busco G 1 , Greco MR 1 , Capulli M 2 , Casavola V 1 , Campana M 1 , Teti A 2 ,
Reshkin SJ 1
1Dept. General and Environmental Physiology, University of Bari, Italy; 2Dept. Experimental
Medicine, University of L’Aquila, Italy
12

_______________________________________________________________________________
General information
Venue
CNR – Consiglio Nazionale delle Ricerche – Piazzale Aldo Moro n. 7, 00185 Rome (Italy)
Scientific Secretariat
Prof. Anna Teti, Dr. Rita Di Massimo – Department of Experimental Medicine – University of
L’Aquila
Tel.:+39 0862 433511/10 – Fax: +39 0862 433523 – E-mail: bonesecr@univaq.it
Organizing Secretariat
CENTRO ITALIANO CONGRESSI C.I.C. srl – Corso Trieste, 42 – 00198 Rome (Italy)
Tel.: +39 06 8412673 – Fax: +39 06 8412687 – E-mail: congressi@gruppocic.it
Call for abstracts
Late breaking abstract submission open. Deadline 15 November 2007.
All abstract must be submitted in English and must be e-mailed to bonesecr@univaq.it
Language
The official language is English
Registration fee (VAT included)
The registration fee includes: admission to the scientific meetings, conference kit, coffee breaks and
lunches.
By 31 July By 30 November After 30 November 2007
MetaBre/BRECOSM partners € 240.00 € 240.00 € 240.00
Students/Trainees € 200.00 € 200.00 € 200.00
Others € 240.00 € 300.00 € 350.00
How to register
Please download the registration form or register online through the meeting website at
www.metabre.org. Please note that the registration form is to be used to register one participant
only and, if applicable, their accompanying person(s). A regular invoice will be sent as confirmation
of registration.
Hotel accommodation
Accommodation form can be downloaded at www.metabre.org. Please note that currently only
HOTEL VILLA FLORENCE is still available.
Please send the form along with the deposit for one night as indicated in the form.
Attendance certificate
An attendance certificate will be available at the end of the meeting.
13

Public transport
The C.N.R. is about 40 minutes by taxi from “Leonardo Da Vinci” airport and “Ciampino” airport
(official fare approx € 40.00) and 10 minutes walk from Termini Railway Station.
Frequent trains serve “Termini” Station from both airports. Please check the Rome airports website
www.adr.it for further information.
The C.N.R. can be reached from the city center by:
METRO – Line B the “Blue Line”(runs between Rebibbia and Laurentina): TERMINI STOP
– Line A the “Orange Line” (runs between Battistini and Anagnina): TERMINI STOP
Gates open daily at 05:30am and close usually at 11:30pm, except Saturday evenings when closing
time is at 0:30am. Because of the works to renew LINE A, last train may leave earlier. Check at the
Line A stations.
suggested itinerary
14

Oral Communications
Oral communications are scheduled on 5/6/7 December 2007. Each oral presentation has been
allotted 10 minutes: 7 minute presentation plus 3 minute questions.
Presenters must use Powerpoint presentation package. These can be brought on memory sticks for
downloading onto computers (MacOS and Windows) supplied for the Conference.
The Conference Hall will have the following equipment for presentations: multistandard video
projector, video switcher, MacOS- and Windows-based computers, microphones and laser pointers.
Poster session
Posters sessions will be held on:
5 December 2007 – from 5:30 p.m. to 6:30 p.m.
6 December 2007 – from 1:15 p.m. to 2:30 p.m.
Size of the poster: 70 x 100 cm
Contacts
www.metabre.org ; bonesecr@univaq.it - www.centroitalianocongressi.it ; congressi@gruppocic.it
15